MedTrace Logo

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

NCT04837209 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-10-01

No results posted yet for this study

Summary

This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer.

The names of the study treatment involved in this study are:

* Dostarlimab
* Niraparib
* Radiation Therapy (RT), which is given per standard of care.

Conditions

Interventions

DRUG

Niraparib

Capsule, taken by mouth

DRUG

Dostarlimab

Intravenous infusion

RADIATION

Radiation therapy

Radio Therapy

Sponsors & Collaborators

Principal Investigators

  • Steven J Isakoff, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-21
Primary Completion
2027-02-01
Completion
2029-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04837209 on ClinicalTrials.gov